Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06056973
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-28
First Post:
2023-09-18
Brief Title:
Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis
Sponsor:
The First Affiliated Hospital of Dalian Medical University
Organization:
The First Affiliated Hospital of Dalian Medical University
Study Overview
Official Title:
A Multicenter Randomized Controlled Clinical Trial of Jinghua Weikang Capsule for Maintenance Treatment of Reflux Esophagitis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Reflux esophagitis is a common clinical disease pPI or potassium competitive acid blocker P-CAB is the first choice for the treatment of reflux esophagitis However patients with recurrent symptoms and severe esophagitis Los Angeles grade C and D after long-term use of PPI or P-CAB usually need long-term maintenance treatment Attention should be paid to the possible adverse reactions of long-term acid suppression therapy and the interaction between drugs The main efficacy of Jinghua Weikang capsules is regulating qi and dispersing cold clearing heat and removing blood stasis Applicable to cold and heat syndrome qi stagnation and blood stasis caused by epigastric distension pain belching acid reflux noisy bitter taste duodenal ulcer see the above syndrome In the early stage a series of studies were carried out on Jinghua Weikang Capsule which confirmed that Jinghua Weikang Capsule showed the effect of acid inhibition and symptom relief in the treatment of reflux esophagitis and had a synergistic effect when combined with western medicine However Jinghua Weikang Capsule still lacks sufficient evidence to support the reduction of the recurrence rate of reflux esophagitis Therefore we carried out this experiment to explore the clinical efficacy of Jinghua Weikang Capsule in the maintenance treatment of reflux esophagitis so as to reduce the recurrence rate of reflux esophagitis and relieve symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None